Showing posts with label copyright registration in sri lanka. Show all posts
Showing posts with label copyright registration in sri lanka. Show all posts

Wednesday, 28 October 2020

A careful dissection of the Madrid System



It is appropriately established that the Madrid System is bifurcated into the Madrid Agreement (1891) and the Madrid Protocol (1989). It was a welcoming introduction in the realm of trademarks for it sought to marshal and leave tangle-free the filing of trademarks abroad, which was regarded as being quintessential since trademark laws in all jurisdictions vary in practice. The system, alongside the many added benefits, enables a streamlined filing procedure with a modest fee, decreasing the quantum of applications to be filed for a single mark.

To give a brief overview, availing the benefits entailed in the Madrid System requires an applicant to file a national trademark application, also known as the ‘Basic application.’ The proprietor is then eligible to file a request for International Registration (IR) of marks, which is a means of progressing and increasing the outreach of the application to the designated states.

Process of Filing

Fig1: Process of Filing

Although the two contribute to the creation of the Madrid system, per se, there are differences found within the two bifurcations since the Protocol aimed at overcoming the problems within the Agreement. Therefore, the key features of the Protocol can be contrasted with the Agreement as per the points of differences mentioned below:

  • Primarily, as per the Madrid Protocol, a ‘Basic application’ would also suffice for the filing of an IR contrary to just the basic registration.
  • Also, where the Agreement requisitioned French as the only official language, the Protocol added English and Spanish to the list of workable languages.
  • Furthermore, the Protocol limits the period for notification of refusal of the IR to a period of 12 months to 18 months, where the Agreement resorted to a twelve-month window period. The Protocol enables a prompt establishment and centralized manner of controlling rights emanating out of registration.
  • Lastly, the scope of protection of marks is 20 years as per the Agreement, whereas the Protocol limits it to 10 years, which is further subject to renewal in both cases.

It might appear trivial to pluck out any blemishes in the system after 31 years of successful enforcement; however, it seems to be pertinent to uncover the positives as well as the negatives before actually resorting to either of the two routes for seeking protection of marks.

The gravest issues arising under the Madrid System is the issue of ‘central attack,’ which contemplates the fact that since the foundation of the application is based on one national application, in the event of cancellation or abandonment or proven invalidation, the same would naturally result in the automatic cancellation of all ancillary protections sought through the System. The situation can indeed be recovered from since the Madrid Protocol facilitates a procedure for conversion of International Registrations (IRs) into national applications for each of the designated states within three consequent months after paying due consideration. Contrary to the Madrid Protocol, the Madrid Agreement provides no such remedy. However, this hurdle has a fixed tenure of 05 years after which any harm to the basic application would not affect rights protected abroad since, after the lapse of the five-year period, IRs become independent of the national registration.

Furthermore, international registrations follow a strict timeline of processing, which is eighteen months. Quite often, the applications at the national phase are not processed by then, frequently leading to untimely objections and concerns, which could economically be very damaging for the proprietor of the concerning trademark.

Another added disadvantage here is that where on the one hand, it is popularly acclaimed that intellectual property rights are easily transferable – the Madrid System, on the other hand, limits this right only to the convention countries. Thereby, once the Madrid route is taken, assignment or transfer of rights beyond convention countries is not permissible; the proprietor then has to convert the mark into a local mark, which is not only heavy on the pocket but also a complex procedure. Thus, this could be disadvantageous where a potential opportunity from non-Madrid abiding countries is encountered for probable profitable sales or assignment of rights. Also, a handful of the countries do not acknowledge registration certificates issued under the aegis of WIPO, which ultimately implies resorting to the aid of national trademark offices for a recognized certificate at an additional cost.

In addition to this lies the problem of making modifications to the classification in the Madrid-based application. It is permissible to wipe-out, but making additions to the classification to broaden the admissibility of the said application, is not permissible. Any material or non-material changes to the mark are also not warranted.

Scale of disadvantages

Fig.2: Scale of disadvantages

Although it may be appealing to blindly resort to the Madrid Protocol as it offers to be a ‘one-stop-shop’ for one’s effort to trademark coupled with the benefit of a simple yet speedy examination (as acclaimed) and a cost-effective approach by delineating the need of a local council, it is imperative to take into consideration the limitations mentioned above. Hence, it is highly advisable to conduct a cost-benefit analysis of the number of jurisdictions along with the practices opted therein since all jurisdictions are not tenable to the Protocol. Also, comprehensive searches in designated jurisdictions need to be conducted to uncover prior marks, which otherwise could prove harmful in the aftermath. A concrete branding strategy ought to be put in place to avail of the maximum potential value of the trademark at hand. 👉 ✅  For view source:  https://bit.ly/34A4B4E

 

Don’t forget to follow us on social media:

Facebook – https://www.facebook.com/kashishipr/

Twitter – https://twitter.com/kashishipr

Linkedin – https://www.linkedin.com/company/kashishipr/

Pinterest – https://www.pinterest.com/kashishipr/

Tumblr – https://kashishipr.tumblr.com/

 

 

Contact - US

Email Id: kashishipr@kashishipr.com

Website: www.kashishipr.com

Monday, 6 April 2020

Biocept Inc Receives Patent for its Primer-Switch Technology in Australia


patent protection

Biocept Inc., (a San Diego-based commercial-stage cancer diagnostics company providing liquid biopsy tests for doctors and their patients with cancer) has quite recently won a new patent in Australia. The granted patent provides Intellectual Property (IP) Protection to Biocept's Primer-Switch technology that is efficient and useful in performing ctDNA (circulating tumor DNA) analysis with the help of real-time PCR and associated analysis methods, such as next-generation sequencing (NGS).
The chief scientific officer at Biocept, Lyle Arnold, stated that the grant of the new patent expands the company's robust IP protection for rare mutation detection. He further said that the Primer-Switch is a method capable of detecting the rare genetic events, and is an addition to Biocept's Switch-Blocker technology, which is used in a routine with the company's ctDNA Target Selector assays.
Arnold mentioned that it is indeed the first patent issued for Biocept's Primer-Switch technology, which the company believes would end up achieving worldwide Patent Protection. He also added that the granted patent is now another tool in Biocept's toolkit of methods, which shall inform on biomarkers to help physician decision-making in the treatment of cancer patients. Moreover, the company explained that the Australian patent describes another exclusive method for particularly enriching patient specimens for oncogene mutations of interest.
The Primer-Switch technology is proactively used as a critical part of PCR reactions, which are integral to the most commonly-used method of amplification in diagnostic assays. The Primer-Switch methodology holds immense potential for finding diverse use in PCR reactions, specifically, in scenarios where there is a need to detect rare genetic events or have way more precise PCR amplification.
Michael Nall, the CEO at Biocept Inc, stated that the expansion of Biocept's IP would continue to be the global validation of its technology, which, in turn, would position the company as a provider of cutting-edge approaches to detect rare genetic events with the help of blood and other fluids. He also said that Biocept would keep coming up with innovative technologies and products like Primer-Switch to stay ahead of the curve in liquid biopsy technology. For more visit: https://www.kashishipr.com/ 


Don’t forget to follow us on social media:









Contact - US